ProCE Banner Activity

KEYNOTE-667 High-Risk Group Update: Pembrolizumab + COPDAC-28 Consolidation in Children and AYA cHL

Capsule Summary
Conference Coverage
Slideset

The addition of pembrolizumab to COPDAC-28 consolidation in children and AYA patients with high-risk cHL and slow response to initial chemotherapy was associated with durable responses and acceptable safety.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Geron, Jazz Pharmaceuticals, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AbbVie

Geron

Jazz Pharmaceuticals

Lilly

Merck Sharp & Dohme Corp.

Novartis